During my B.pharma years I did my internship in Orgenon India, followed by Dey's medical, a good experience of working in a manufacturing plant where in you have GMP compliances. At that point of time Pfizer was taking over Warner pharma and then I started looking at this big companies history and series of merger and acquisitions. Both Novartis and Pfizer have a very hyper competitive environment; my view point has been developed after series of discussions with ex employs of both of this organization. Pfizer was also the first company where in I joined for marketing rep position in year 2001.
Pfizer blockbuster lipitor became off patent last year and this year Pfizer has good hope for Tofacitinib for which average sales is expected to be $2.2 Bn...But if we look at the company's pipeline they do not have extensive pipeline like some scientific global companies. So strategy going forward for Pfizer is to buy late stage molecules. Now time will say that late stage compound buy outs will help it to still maintain its global position or its going to lose its market to hyper aggressive competitor Novartis
No comments:
Post a Comment